Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C9RC
|
||||
| Former ID |
DPR000081
|
||||
| Drug Name |
NPY antagonist
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Preclinical | [1] | ||
| Company |
Amgen
|
||||
| CAS Number |
CAS 262418-00-8
|
||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor 5 | Target Info | Antagonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.